Bayer, Evotec Alliances Create 'Virtual' Specialized Businesses With Finite Goals
Executive Summary
On the sidelines of the BIO-Europe partnering conference, held in Cologne, Germany, Dr Joerg Moeller, head of development for Bayer's pharmaceuticals division, and Evotec CEO Dr Werner Lanthaler tell Scrip why their partnerships work and what challenges they have overcome to create short-term syndicated businesses with specific therapeutic focuses.
You may also be interested in...
Deal Watch: Early 2020 Deal-Making Boom Starts With Third Bayer/Evotec R&D Alliance
The JP Morgan conference uptick in biopharma deal-making has begun with more than 20 deals announced this week, including the latest Bayer/Evotec partnership and Pfizer’s cancer tie-up with eFFECTOR.
Deal Watch: Bristol Shores Up Cancer, NASH Pipelines With International Deals
Partnership with France’s Enterome will add a microbiome aspect to Bristol’s immuno-oncology efforts, while its license of Japanese firm Nitto Denko’s siRNA technology could bolster NASH combo therapy development. Meanwhile, Eagle moves into biosimilars with the purchase of Arsia for up to $78m.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.